Schechter Investment Advisors LLC Has $396,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Schechter Investment Advisors LLC boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 55.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,494 shares of the medical equipment provider’s stock after purchasing an additional 1,968 shares during the period. Schechter Investment Advisors LLC’s holdings in Hologic were worth $396,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of HOLX. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at $26,000. Groupama Asset Managment grew its holdings in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC increased its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. increased its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.4 %

HOLX opened at $62.08 on Thursday. The firm’s fifty day moving average is $68.77 and its two-hundred day moving average is $75.64. The firm has a market cap of $13.93 billion, a PE ratio of 19.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $61.70 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research reports. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Monday, February 3rd. Morgan Stanley decreased their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Evercore ISI dropped their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.